AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsBone Marrow TransplantationGraft vs Leukemia EffectMyeloablative AgonistsTissue DonorsBusulfanGraft SurvivalTreatment OutcomeVidarabineRemission InductionRecurrenceGraft vs Tumor EffectHistocompatibility TestingLymphocyte TransfusionHematopoietic Stem CellsCord Blood Stem Cell TransplantationImmunosuppressive AgentsWhole-Body IrradiationLeukemia, Myeloid, AcuteLeukemiaMultiple MyelomaRetrospective StudiesCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsCytomegalovirus InfectionsMinor Histocompatibility AntigensLymphocyte DepletionSalvage TherapyHistocompatibilityDisease-Free SurvivalAntilymphocyte SerumSurvival AnalysisLiver TransplantationMyelodysplastic SyndromesSurvival RateVirus ActivationNeoplasm, ResidualChimerismPrecursor Cell Lymphoblastic Leukemia-LymphomaMelphalanHematopoietic Stem Cell MobilizationMesenchymal Stem Cell TransplantationTime FactorsHepatic Veno-Occlusive DiseaseCyclophosphamideAntigens, CD34T-LymphocytesAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusCell TransplantationAnemia, AplasticAcute DiseasePrimary MyelofibrosisHLA AntigensEmbryonic Stem CellsHematologic DiseasesKidney TransplantationFollow-Up StudiesTransplantation ImmunologyImmunosuppressionLeukemia, Myeloid, Accelerated PhasePrognosisAntibodies, NeoplasmRoseolovirus InfectionsAdult Stem CellsCytarabineLeukemia, MyeloidGraft RejectionBenzamidesGranulocyte Colony-Stimulating FactorImmunocompromised HostLymphoproliferative DisordersAntineoplastic AgentsFusion Proteins, bcr-ablHodgkin DiseaseBone Marrow CellsNuclear FamilyReceptors, Purinergic P2X5PyrimidinesLymphoma, Non-HodgkinCell DifferentiationTransplantation, IsogeneicFlow CytometryInfectionGanciclovirCyclosporineLeukocyte TransfusionImmunotherapy, AdoptivePiperazinesHeart Transplantation
HSCTMarrow TransplantationDestroyed tissue anGraft-versus-Hematologic MalignanciesChemotherapyBone marrow traTransplantsRegimenAbstractTransplanting allogeneic hematopoieticConditioning regimensHaploidenticalImmuneRelapse after allogeneicBlood stemProgenitor cellFollowed by hematopoieticOutcomesNonmyeloablativeTherapyNeutrophil engraftmentLymphoidRecipientsTherapeuticComplicationsChimerismTotal body irradiPlatelet engraftmentTrialsGvHDClinically relevant levelsUmbilical cordAutologous transplantationTherapiesImmunosuppressionPeripheralAmerican Society ofHigh-doseMyeloidDonorsHaematopoieticPediatric2022Myelodysplastic syndromeMorbiditySurvivalMedianDonor cells
HSCT38
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • The most common adverse event following allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD), which can increase morbidity and mortality in HSCT patients. (oncologynurseadvisor.com)
  • The leading cause of GVHD is hematopoietic stem cell transplantation (HSCT), most commonly allogeneic (between two individuals) rather than autologous (from the same individual). (medscape.com)
  • In allogeneic HSCT, donor T cells target malignant hematopoietic cell populations, creating a graft-versus-tumor effect. (medscape.com)
  • Despite attempts to manipulate the immune response before, during, and after transplantation, GVHD remains a primary cause of morbidity and mortality after HSCT. (medscape.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) and coronavirus disease 2019 (COVID-19) infection can both lead to severe cytokine release syndrome (sCRS) resulting in critical illness and death. (akjournals.com)
  • In this single institution, preliminary comparative case-series study we compared clinical and laboratory co-variates as well as response to tocilizumab (TCZ)-based therapy of 15 allogeneic-HSCT- and 17 COVID-19-associated sCRS patients. (akjournals.com)
  • Reaction to a TCZ plus posttransplant cyclophosphamide (PTCY) consolidation therapy in the allogeneic-HSCT-associated sCRS group yielded significantly inferior long-term outcome as compared to TCZ-based therapy in the COVID-19-associated group ( P = 0.003). (akjournals.com)
  • Serum levels of cytokines and chemokines show similar changes in allogeneic-HSCT- and COVID-19-associated sCRS with marked elevation of interleukin-6 (IL-6), regulated upon activation normal T-cell expressed and secreted (RANTES), monocyte chemoattractant protein-1 (MCP-1) and interferon γ -induced protein 10 kDa (IP-10) levels. (akjournals.com)
  • In addition, levels of IL-5, IL-10, IL-15 were also elevated in allogeneic-HSCT-associated sCRS. (akjournals.com)
  • Our multi-cytokine expression data indicate that the pathophysiology of allogeneic-HSCT and COVID-19-associated sCRS are similar therefore the same clinical grading system and TCZ-based treatment approaches can be applied. (akjournals.com)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The overall and sustained clinical benefit of omidubicel makes it an important addition to the options for allogeneic HSCT. (gamida-cell.com)
  • The ability to correct genetic hematopoietic diseases by gene therapy has a number of advantages over current therapies that involve allogeneic hematopoietic stem cell transplantation (HSCT). (nih.gov)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
  • Background: The use of total body radiation (TBI) before hematopoietic stem cell transplantation (HSCT) would increase the engraftment without transplant-related morbidity or mortality among Thalassemia major (TM) cases. (sumathipublications.com)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. (blood-genomics.com)
  • This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT ( n =68) or human leukocyte antigen (HLA)-matched HSCT ( n =51). (blood-genomics.com)
  • There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. (blood-genomics.com)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • The growing need for haematopoietic stem cell transplantation (HSCT) is reflected in the increasing number of transplants performed globally each year. (bvsalud.org)
Marrow Transplantation12
Destroyed tissue an1
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
Graft-versus-4
  • Currently, my work aims to establish strategies to reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease or interfering with donor stem cell engraftment. (stanford.edu)
  • Previously, acute graft versus host disease (GVHD) required symptoms within the first 100 days of transplantation and chronic GVHD after day 100. (medscape.com)
  • Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis. (u-tokyo-hemat.com)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
Hematologic Malignancies5
  • Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies. (cdc.gov)
  • NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. (sagepub.com)
  • I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). (dukecancerinstitute.org)
  • Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies (blood cancers), for which it has been granted Breakthrough Status and orphan drug designation by the FDA. (gamida-cell.com)
  • In the last two decades allogeneic hematopoietic cell transplantation (HCT) has been used with increasing frequencies in hematologic malignancies with curative intent. (haematologica.org)
Chemotherapy13
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • An environment for GVHD is formed when antigen-presenting cells are activated by the patient's disease and the pretreatment destruction of cells caused by chemotherapy and radiotherapy. (oncologynurseadvisor.com)
  • A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL Rochester, Minn., Jacksonville, Fla. (mayo.edu)
  • Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (mayo.edu)
  • Mobilization human CD34+ cells for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5-day treatment cycle with G-CSF and a 1-2 day apheresis procedure. (biokine.com)
  • Conditioning treatment - administration of chemotherapy and/or radiation to the patient in order to destroy all of the diseased cells in the body and to create space in the bone marrow for the transplanted stem cells to populate. (uchicagomedicine.org)
  • Post-transplant care - including regular examinations to monitor allogeneic transplant patients for signs of graft vs. host disease (GVHD) and to watch autologous and allogeneic patients for immune system recovery, complications related to chemotherapy or radiation and cancer recurrence (relapse). (uchicagomedicine.org)
  • Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. (shengsci.com)
  • abstract： PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
Bone marrow tra6
  • Dr. Tisdale and his colleagues recently completed a modified bone marrow transplant strategy for the first time in adult patients with sickle cell disease. (nih.gov)
  • It should be emphasized that all the patients included in this trial had the more severe form of this immune deficiency and were not eligible for an allogeneic bone marrow transplant. (inserm.fr)
  • The company also highlighted progress with omidubicel , an advanced cell therapy with positive Phase 3 clinical data, as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell (bone marrow) transplant, and GDA-201 , a natural killer (NK) cell immunotherapy in Phase 1/2 development for patients with non-Hodgkin lymphoma (NHL). (biospace.com)
  • During the quarter, Gamida Cell continued to advance omidubicel, the first cell therapy for bone marrow transplant to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). (biospace.com)
  • A key milestone in a patient's recovery, neutrophil engraftment is a measure of how quickly the stem cells a patient receives in a bone marrow transplant are established and begin to make healthy new cells. (biospace.com)
  • Additionally, the study met key secondary endpoints related to the speed of platelet engraftment, decrease in infections and reduction in hospitalizations, all significant clinical measures in bone marrow transplant. (biospace.com)
Transplants7
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • Allogeneic transplants involve grafts from a genetically nonidentical donor of the same species and are the transplant type most often used in children. (oncologynurseadvisor.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • February 11, 2021 - Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia. (onclive.com)
  • Apamistamab (Iomab-B) conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia (AML), according to interim results from the phase 3 SIERRA trial, which were presented virtually at the 2021 Transplant and Cellular Therapies Meetings. (onclive.com)
  • We have performed approximately 165 allogeneic, primary islet cell transplants and have seen the benefits for patients, but the complications of immunosuppression inhibit broader use of this procedure. (pipelinereview.com)
  • The idea to use transplants of dopa- ment of protocols that allow generation of fully functional mine-producing cells to substitute for the lost midbrain and safe midbrain dopamine neurons from stem cells. (lu.se)
Regimen9
  • The pharmacokinetics of BUSULFEX were studied in 59 patients participating in a prospective trial of a BUSULFEX-cyclophosphamide preparatory regimen prior to allogeneic hematopoietic progenitor stem cell transplantation. (nih.gov)
  • In addition, this procedure gives therapeutic advantages of a fetal environment like acceptance of unmatched allogeneic donor cells within the pre HDAC9 list immune fetus and engraftment devoid of the will need for conditioning regimen within the rapidly expanding bone marrow (BM) niche. (betadesks.com)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. (mayo.edu)
  • Prospective Clinical Trial of BUSULFEX: The prospective trial was a single-arm, open-label study in 61 patients who received BUSULFEX as part of a conditioning regimen for allogeneic hematopoietic stem cell transplantation. (clustermed.info)
  • We used a clinically acceptable regimen of hematopoietic stem cell transplantation to establish mixed donor/host blood cell chimerism and immune tolerance in a canine model of Duchenne muscular dystrophy ( cxmd ) [ 9 ]. (biomedcentral.com)
  • Case presentation: A 2-year-old female child, diagnosed with TM was scheduled for haploidentical allogenic transplant-based protocol, and after that, based on protocol she was scheduled to undergo a single session of TBI as a conditioning regimen before haploidentical allogenic hematopoietic stem cell tranplant. (sumathipublications.com)
  • A 13-week regimen of systemic immunosuppression was initiated 1 week before transplantation. (medscape.com)
  • One to two days before your stem cell infusion, you'll take a regimen of drugs to help prevent GVHD. (drcremers.com)
Abstract2
  • In total, Gamida Cell is presenting two oral and six poster presentations at TCT 2022, including an oral presentation that was selected as a TCT Best Abstract. (gamida-cell.com)
  • abstract： PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
Transplanting allogeneic hematopoietic1
  • Dr. Flake was the first to investigate the therapeutic potential of in utero stem cell transplantation (IUSCT) for treating hematopoietic and other genetic disorders by demonstrating that transplanting allogeneic hematopoietic cells early in gestation achieve clinically significant levels of hematopoietic chimerism. (chop.edu)
Conditioning regimens4
  • These infections occur as a consequence of transplant conditioning regimens designed to eliminate not only malignant cells but also host immune cells that might interfere with stem cell engraftment. (nih.gov)
  • Herein, we propose that access to the fetal BM HSC niche must also be of prominence, for engraftment in the absence of conditioning regimens is often a competitive method between donor and recipient HSCs for populating limited niche space (11, 12). (betadesks.com)
  • This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP). (umn.edu)
  • More specifically, the development of minimal intensity or so called "nonmyeloablative" conditioning regimens paved the way towards the application of allogeneic HCT in older patients and all of those who probably would not tolerate classical intensity conditioning. (haematologica.org)
Haploidentical3
Immune20
  • The result is a transient period of immune compromise when hematopoietic stem cell transplant recipients are at risk of infectious complications associated with both latent (cytomegalovirus, Epstein-Barr virus, BK virus, human herpes virus 6, herpes simplex virus, varicella-zoster virus) and community-acquired viruses including adenovirus, respiratory syncytial virus, and parainfluenza virus. (nih.gov)
  • GVHD occurs when donor immune cells recognize and attack host antigens. (medscape.com)
  • Rodent models of IUHSCT have also proved useful, specifically together with the availability of recipients lacking particular immune cells. (betadesks.com)
  • However, the IUHSCT of human donor cells into immune competent models, mice (five) or sheep (six, 7), leads to only low levels of engraftment in those recipients that do engraft, which can be also a important reflection of limitations facing patients in actual clinical settings. (betadesks.com)
  • Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection, which is currently achieved by matching for human leukocyte antigen (HLA) expression, immunosuppression, and/or delivery of donor-derived cells to sanctuary sites. (ashpublications.org)
  • Her clinical and translational research explores whether certain immune cells called natural killer (also known as NK cells) can prevent relapse and treat high-risk cancers. (seattlechildrens.org)
  • The issue of immune tolerance is, of course, central to transplantation research. (nih.gov)
  • Dr. Tisdale has an active research program in trying to characterize tolerance and create conditions in which patients will more easily tolerate donor cells and tissues without the need for destroying the immune system or perpetual use of immunosuppressant drugs. (nih.gov)
  • In a recent study, they demonstrated that they could transplant bone marrow cells from HLA-matched sibling donors without needing to completely destroy the patient's immune system. (nih.gov)
  • Third, use of autologous hematopoietic stem cells would be expected to enhance immune reconstitution after transplant. (nih.gov)
  • The increased understanding of immune tolerance and allogeneic antileukemic immune reactivity has led several investigators to develop optimized conditioning protocols and new strategies to manipulate the effector cells either within the graft or in vivo . (haematologica.org)
  • As stated above, the fine tuning of the allogeneic immune response by T-cell depletion or pharmacological means represents the second important pillar in the development of optimized transplantation protocols. (haematologica.org)
  • The study is designed with endpoints of safety, cell survival, immune evasion, and C-peptide production. (pipelinereview.com)
  • As with any organ transplant, suppression of the recipient's immune system is required to prevent immune rejection of the transplanted cells. (pipelinereview.com)
  • In addition to complications from this immune suppression, inadequate immunosuppression has limited uptake and durability of effect, as most patients eventually reject the transplanted islets over months to years, lose glucose control, and become insulin-dependent again, primarily due to immune rejection of the allogeneic islets from inadequate immunosuppression. (pipelinereview.com)
  • Sana's hypoimmune technology seeks to overcome the immunologic rejection of allogeneic cells via disruption of human leukocyte antigen (HLA) class I and class II expression to allow cells to evade the adaptive immune system, including antibody and T cell responses, as well as overexpression of CD47 to allow cells to evade the innate immune cell system, in particular macrophages and natural killer (NK) cells. (pipelinereview.com)
  • If UP421 successfully overcomes immunologic rejection, it may result in engraftment, survival, and C-peptide production in patients with type 1 diabetes following transplantation without immune suppression. (pipelinereview.com)
  • Sana's prior presentations across multiple preclinical models have highlighted the potential of this platform to enable allogeneic cells to evade immune recognition and the potential of hypoimmune-modified cells as a therapeutic for patients. (pipelinereview.com)
  • Despite the heterogeneity in the pathogenesis of immune defects, common cutaneous manifestations and typical infections can provide clinical clues in diagnosing this pediatric emergency. (medscape.com)
  • 1. Definition: GVHD develops when the donor's immune cells mistakenly attack the patient's normal cells. (drcremers.com)
Relapse after allogeneic1
  • Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. (nature.com)
Blood stem5
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
  • The standard treatment is blood stem cell transplant, but outcomes are dependent on finding the disease early. (umn.edu)
  • In the absence of an HLA-compatible donor, the research teams have proposed a treatment by gene therapy which consists of taking blood stem cells carrying the genetic anomaly from patients (CD34+ hematopoietic stem cells), then correct in the laboratory by introducing the healthy WAS gene using a lentiviral vector developed by Anne Galy's team at Généthon, where the clinical batches of vectors were also produced. (inserm.fr)
  • Blood stem cells are taken through a painless process called apheresis. (uchicagomedicine.org)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
Progenitor cell1
  • Flow cytometric applications for CD34+ cell identification and enumeration provide a rapid, quantitative and reproducible method to evaluate the progenitor cell population. (bdbiosciences.com)
Followed by hematopoietic1
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
Outcomes4
  • Bio My research is focused on using preclinical models to develop novel therapies which improve outcomes for patients receiving allogeneic hematopoietic stem cell transplantation. (stanford.edu)
  • Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. (mcw.edu)
  • Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • Of the 26 patients, 24 (92%) developed areas of subretinal pigmentation that did not correlate with cell dose or visual acuity outcomes. (medscape.com)
Nonmyeloablative5
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • This provoked us to examine long haul lymphocyte reconstitution and thymic work in 80 patients given allogeneic fringe blood foundational microorganisms after nonmyeloablative molding. (scitechnol.com)
  • Heredity explicit chimerism studies are regularly acquired at a few time guides after nonmyeloablative hematopoietic cell transplantation toward evaluate the rhythm and level of engraftment, and to screen join dismissal. (scitechnol.com)
  • Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. (sagepub.com)
Therapy25
  • 1 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital. (nih.gov)
  • However, the clinical success of this therapy is marred by the morbidity associated with viral infections, which are frequent (cytomegalovirus 15.6-28%, adenovirus 3-21%, BK virus 18.5-20.7%) post-transplant. (nih.gov)
  • These cases highlight the variability of clinical features, maternal and neonatal disease, and current lack of effective therapy for maternal RSV infection. (cdc.gov)
  • Dr. Flake is a general pediatric surgeon with a clinical and research focus on prenatal treatment ranging from the fetal surgical repair of anatomic anomalies to prenatal stem cell and gene therapy. (chop.edu)
  • Dr. Flake's research focuses on prenatal treatment ranging from the fetal surgical repair of anatomic anomalies to prenatal stem cell and gene therapy. (chop.edu)
  • The bone marrow- and adipose tissue-derived MSCs were cultured under human platelet lysate conditions and their biological characteristics evaluated for cell therapy (morphology, immunophenotype, colony-forming unit-fibroblast efficiency, proliferation capacity, potential for mesodermal differentiation, secreted proteins, and immunomodulatory effects). (biomedcentral.com)
  • However, one important question that remains to be answered is which cell is more effective and suitable for cell therapy. (biomedcentral.com)
  • In the study, patients with active, relapsed, refractory AML are randomized 1:1 to receive either apamistamab conditioning therapy and allogeneic HCT or conventional care. (onclive.com)
  • A041501, A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL Rochester, Minn. (mayo.edu)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • 27, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced updated one-year post-transplant data presented on omidubicel at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT), being held in Salt Lake City, UT , April 23-26, 2022 . (gamida-cell.com)
  • The vectors and methods identified in these studies will be used in future clinical trials of ex vivo gene therapy. (nih.gov)
  • First, the use of autologous hematopoietic stem cells for gene therapy obviates the need for a matched bone marrow donor since each individual would serve as his or her own bone marrow stem cell donor. (nih.gov)
  • Teams from the AP-HP, University of Paris, Inserm, within the Imagine Institute, the University College of London, and Généthon, have carried out work on treatment by gene therapy consisting of transplanting the patient's own genetically modified hematopoietic stem cells as part of a phase I/II clinical trial, promoted by Genethon, in 8 patients with Wiskott-Aldrich syndrome (WAS). (inserm.fr)
  • Evidence suggests that the CXC-chemokine receptor-4 (CXCR4) pathway plays a major role in cancer cell homing and metastasis and in shaping the tumor microenvironment (TME), and thus represents a potential target for cancer therapy. (biokine.com)
  • Stem cell transplantation is a treatment offered through our pioneering cellular therapy program. (uchicagomedicine.org)
  • Insights from this study may inform development of Sana's SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes. (pipelinereview.com)
  • Combining Sana's hypoimmune technology with primary islet cell transplantation therapy can generate important first-in-human data that may be a step to removing immunosuppression from allogeneic cell transplant in the type 1 diabetes setting. (pipelinereview.com)
  • If a clinical trial is not available, the patient can be treated with standard therapy. (medscape.com)
  • Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability. (mcw.edu)
  • But this is just a first step in the long road towards making regenerative cell therapy a reality in macular and retinal degeneration. (medscape.com)
  • BOSTON--( BUSINESS WIRE )-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended March 31, 2021. (biospace.com)
  • We also continue to expand our clinical pipeline with plans to submit an IND for our GDA-201 natural killer cell therapy, initiate a multi-center Phase 1/2 clinical study in NHL and continue to advance our R&D activities to pursue the development of genetically modified NAM-enabled NK cells in solid tumors. (biospace.com)
  • In February 2021, the company presented details of the results of the omidubicel Phase 3 study at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research. (biospace.com)
  • Cell Therapy for Parkinsons Disease: What Next? (lu.se)
Neutrophil engraftment1
  • The study achieved its primary endpoint , a statistically significant reduction in time to neutrophil engraftment, as well as all key secondary endpoints. (biospace.com)
Lymphoid3
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Contrasted with HLA indistinguishable matched kin giver and matched irrelevant benefactor grown up hematopoietic cell transplantation beneficiaries, quantitative lymphoid recuperation in UCB transplantation beneficiaries is more slow in the initial 3 months, however these distinctions vanished by months after transplantation. (scitechnol.com)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
Recipients5
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • Intramuscular injection of donor muscle-derived cells into chimeric cxmd recipients restored dystrophin expression for at least 24 weeks in the absence of post-transplant immunosuppression, indicating that cell transplantation may be a viable therapeutic option for muscular dystrophy. (biomedcentral.com)
  • In a Phase II study single-agent treatment with BL-8040 showed similar efficacy and non-inferiority in recipient engraftment, with all transplanted recipients successfully engrafting with BL-8040-mobilized grafts. (biokine.com)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
Therapeutic5
  • This novel methodology may serve as a platform for future diagnostic and therapeutic clinical studies targeting the biology of coronary atherosclerotic plaque. (tum.de)
  • Sclerodermatous GVHD has a broad clinical spectrum and presents therapeutic challenges. (medscape.com)
  • Over the past decade, MSCs which are isolated from the umbilical cord, umbilical cord blood, bone marrow (BM), adipose tissue (AT) and many other adult tissues have been explored as potential therapeutic strategies for a number of diseases [ 2 ], but AT and BM are the most widely used sources of MSC, especially in autologous cell-based therapies due to ease of harvest and potential autologous application [ 3 ]. (biomedcentral.com)
  • HLA-A disruption from donor cells is a step toward generating allogeneic cells as an off-the-shelf therapeutic. (ashpublications.org)
  • This allows us to administer a therapeutic dose of cells that may help cancer patients live longer better lives. (gamida-cell.com)
Complications7
  • The aim of this study is thus to define group-based trajectory modeling, to identify clusters of individual serum citrulline kinetics in the early phase of allogeneic HCST, and to test whether these unsupervised trajectories were correlated with these early complications. (confex.com)
  • Thus, a number of groups have explored the clinical potential of adoptively transferred virus-specific T cells (VSTs) as an approach to prevent/treat virus-associated complications. (nih.gov)
  • My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. (dukecancerinstitute.org)
  • The data showed sustained clinical benefits in the first-year post-transplant with omidubicel, as demonstrated by significant reduction in infectious complications. (gamida-cell.com)
  • The more severe clinical phenotype is characterized by severe infections, bleeding, eczema and manifestations of autoimmunity with a significant risk of developing tumor complications. (inserm.fr)
  • In the article which has just been published in Nature Medicine, the long-term clinical and biological results (median follow-up of 7.6 years) of the phase I/II trial in 8 patients with WAS are described with a special attention paid to two serious complications of this disease: thrombocytopenia and autoimmunity. (inserm.fr)
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (longdom.org)
Chimerism1
  • In this review, a review examination was performed to survey the transfer result of grown up patients with ALL who had chimerism investigations of unfractionated BM cells or fringe blood subsets performed roughly 80 days after transplantation. (scitechnol.com)
Total body irradi1
Platelet engraftment1
  • The median times for neutrophil and platelet engraftment were 13.5 and 12 days, respectively, and did not differ between the two cohorts. (nature.com)
Trials12
  • METHODS: We performed targeted sequencing in 309 patients age 50-75 years with International Prognostic Scoring System (IPSS) intermediate-2 or high-risk MDS, enrolled in the Blood and Marrow Transplant Clinical Trials Network 1102 study and assessed the association of gene mutations with OS. (bvsalud.org)
  • This article discusses the current status of clinical trials of rituximab to treat GVHD in the pediatric population. (oncologynurseadvisor.com)
  • He has been involved in numerous clinical trials, including randomized trials comparing prenatal and postnatal repair of congenital diaphragmatic hernia and a trial comparing prenatal and postnatal repair of myelomeningocele . (chop.edu)
  • To support evidence-based clinical guidelines on erythropoietin use for anemia in oncology, we conducted systematic reviews of controlled trials on four patient groups. (cancernetwork.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • Safety and robust efficacy had previously been demonstrated with the agent in 271 patients treated in 9 different phase 1 and 2 clinical trials. (onclive.com)
  • We have several clinical trials to treat patients with ALD, and we have published extensively on the clinical aspects of ALD, including biomarkers, oxidative stress, neuropsychology, and imaging. (umn.edu)
  • Moreover, xenotransplantation accurately predicted results in canine-to-canine allogeneic transplantation experiments, an important pre-clinical model for future human clinical trials. (biomedcentral.com)
  • As a result, all patients should be evaluated for entry into well-designed clinical trials. (medscape.com)
  • While some patients in her study have gained vision, Ninel Z. Gregori, MD, from Bascom Palmer Eye Institute, Miami, Florida, said, "These trials show long term safety and possible biologic activity of pluripotent stem-cell derived progeny, but they were not powered to show efficacy. (medscape.com)
  • Dr Gregori and her multi-institutional team conducted two phase 1/2 trials using hESC-derived RPE cells, one in dry AMD patients (n = 13) and the other in Stargardt disease (n = 13). (medscape.com)
  • Early Clinical Trials et al.23). (lu.se)
GvHD12
  • Treatment focuses on blocking the expansion of donor T cells, as GVHD develops from the expansion of these cells. (oncologynurseadvisor.com)
  • CD20 antagonists deregulate B cells, which are believed to contribute to the pathogenesis of GVHD. (oncologynurseadvisor.com)
  • When CD20 antagonists decrease the amount of circulating B cells, the body may not produce as many cytotoxic T cells that can potentially induce GVHD. (oncologynurseadvisor.com)
  • Many factors affect the balance between a graft-versus-tumor effect and GVHD, including genetic differences between donor and host and the magnitude of the T-cell response. (medscape.com)
  • Treatment for acute GVHD, which occurs during the transplantation recovery phase, is performed in an inpatient setting. (medscape.com)
  • In acute GVHD, CXCL10 and B-cell-activating factor may be predictive biomarkers. (medscape.com)
  • In chronic GVHD and acute GVHD, CXCL10, CXCL11, and B-cell-activating factor can be used as diagnostic biomarkers. (medscape.com)
  • Acute GVHD occurs most frequently 30-40 days after engraftment. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • As opposed to the aggravated circumstance in GVHD, when communication happens between enacted APC and benefactor T cells, the tissue harm brought about by myeloablative alloSCT brings about dermal enrollment of HLA class II-positive tissue fixing macrophages coinciding with expanded quantities of patient and contributor determined T cells, however without indications of explicit connection and commencement of a safe reaction. (scitechnol.com)
  • Acute GVHD can occur soon after the transplanted cells begin to appear in the recipient. (drcremers.com)
Clinically relevant levels2
  • He continues to study the requirements to engraftment and developed a pre-clinical canine model of IUSCT in which he has achieved clinically relevant levels of donor engraftment with a goal of prenatal treatment of hemoglobinopathies. (chop.edu)
  • Immunological hurdles to achieving clinically relevant levels of engraftment that have lately been identified involve maternal alloantibodies, maternal T cells, and recipient NK cells (8-10). (betadesks.com)
Umbilical cord1
Autologous transplantation1
  • A Phase 3, randomized, double-blind, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of BL-8040 in combination with G-CSF, compared to placebo and G-CSF, for the mobilization of CD34 cells for autologous transplantation in multiple myeloma patients have already initiated. (biokine.com)
Therapies4
  • Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapies. (biomedcentral.com)
  • Our NAM-enabling technology is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. (gamida-cell.com)
  • Gamida Cell is pioneering a proprietary NAM-enabled immunotherapy pipeline of diverse potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases. (gamida-cell.com)
  • Gene and cell therapies present novel alternatives to disease management, offering the promise of a single treatment and a lifelong cure. (bvsalud.org)
Immunosuppression3
Peripheral3
American Society of2
  • In 1998, the American Society of Hematology (ASH) and theAmerican Society of Clinical Oncology (ASCO) jointly nominated the topic'Uses of Erythropoietin in Oncology' to AHRQ for an Evidence-basedPractice Center systematic review and evidence report. (cancernetwork.com)
  • 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. (nih.gov)
High-dose2
Myeloid5
  • A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) Jacksonville, Fla., Rochester, Minn. (mayo.edu)
  • Criteria for discharge were presence of myeloid engraftment and absence of severe concomitant problems. (nature.com)
  • Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw , 2017, 15(7): 926−957. (blood-genomics.com)
  • Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. (mcw.edu)
  • DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. (mcw.edu)
Donors1
Haematopoietic2
Pediatric3
20221
  • Gamida Cell initiated a rolling Biologics License Application (BLA) submission for omidubicel in the first quarter of 2022 and is on-track to complete submission of all modules of the BLA in the second quarter of 2022. (gamida-cell.com)
Myelodysplastic syndrome1
Morbidity1
Survival5
  • Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. (sagepub.com)
  • Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. (seattlechildrens.org)
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. (seattlechildrens.org)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • The expectation is that, once in place, the new RPE cells will support or replace the patient's own failing RPE cells and boost the survival of photoreceptors. (medscape.com)
Median1
Donor cells4
  • As such, the murine anemic model and severe combined immunodeficient (SCID) model demonstrate superior engraftment than normal mice following IUHSCT, similar for the observation with SCID individuals exactly where donor cells have an advantage more than recipient HSC for populating the niche (3, four). (betadesks.com)
  • We thus hypothesized that vacating the fetal HSC niche prior to IUHSCT would improve obtainable niche spaces for incoming donor cells. (betadesks.com)
  • However, diprotin A, a positive modulator of CXCR4-SDF-1 binding, significantly enhanced engraftment and stimulated sustained proliferation of donor cells in vivo . (biomedcentral.com)
  • The drying and scarring effects of the attack by the donor cells can affect the inside of the mouth and the esophagus (from the throat to the stomach), causing them to become excessively dry and damaged. (drcremers.com)